Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

To Address Drug Affordability, Grab the Low-hanging Fruit

To Address Drug Affordability, Grab the Low-hanging Fruit News & Analysis The JAMA Forum Michelle M. Mello, JD, PhD, MPhil; Trish Riley, MS ith COVID-19 dominating the news, it is easy to forget that up W until a year ago, the US public’s topdomesticprioritiesforCongresswereim- proving the affordability of health care and prescription drugs. But the need for action has only increased during the pandemic as millions of people in the US lost employer- sponsored insurance, states incurred mas- sive expenses, and prescription drug prices continued their upward march. Notwithstanding the new balance of powerintheUSSenate,makingbigstridesin addressing drug costs at the federal level re- mains challenging. Many potentially useful measures are under consideration in Con- gress,includingrepealoftheMedicaidrebate cap. But despite signs that Congress recog- nizes drug costs as a priority, federal reforms thatsignificantlyeasecostsfacesteepodds. represent a fair return on companies’ invest- In Massachusetts, Gov Charlie Baker None of the political barriers to far-reaching reform that surfaced during the Trump ad- ment in research and development. There- has spearheaded legislation to limit annual fore, they should not increase much over price increases for drugs with average ministration have vanished, and the prevail- ing partisanship and Democrats’ razor-thin time in real terms, absent some extenuat- annual costs of $50 000 or more to http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

To Address Drug Affordability, Grab the Low-hanging Fruit

Mello, Michelle M.; Riley, Trish
JAMA , Volume 325 (16) – Apr 27, 2021
Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/to-address-drug-affordability-grab-the-low-hanging-fruit-zS00TqSZN7

References (6)

Publisher
American Medical Association
Copyright
Copyright 2021 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2021.4619
Publisher site
See Article on Publisher Site

Abstract

News & Analysis The JAMA Forum Michelle M. Mello, JD, PhD, MPhil; Trish Riley, MS ith COVID-19 dominating the news, it is easy to forget that up W until a year ago, the US public’s topdomesticprioritiesforCongresswereim- proving the affordability of health care and prescription drugs. But the need for action has only increased during the pandemic as millions of people in the US lost employer- sponsored insurance, states incurred mas- sive expenses, and prescription drug prices continued their upward march. Notwithstanding the new balance of powerintheUSSenate,makingbigstridesin addressing drug costs at the federal level re- mains challenging. Many potentially useful measures are under consideration in Con- gress,includingrepealoftheMedicaidrebate cap. But despite signs that Congress recog- nizes drug costs as a priority, federal reforms thatsignificantlyeasecostsfacesteepodds. represent a fair return on companies’ invest- In Massachusetts, Gov Charlie Baker None of the political barriers to far-reaching reform that surfaced during the Trump ad- ment in research and development. There- has spearheaded legislation to limit annual fore, they should not increase much over price increases for drugs with average ministration have vanished, and the prevail- ing partisanship and Democrats’ razor-thin time in real terms, absent some extenuat- annual costs of $50 000 or more to

Journal

JAMA – American Medical Association

Published: Apr 27, 2021

There are no references for this article.